Natixis Advisors LLC Boosts Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Natixis Advisors LLC grew its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 69.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,153 shares of the biotechnology company’s stock after buying an additional 11,900 shares during the quarter. Natixis Advisors LLC’s holdings in ADMA Biologics were worth $500,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp lifted its stake in ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after buying an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after acquiring an additional 137,989 shares in the last quarter. Perpetual Ltd purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at $62,300,000. Lord Abbett & CO. LLC acquired a new stake in shares of ADMA Biologics during the third quarter valued at $61,858,000. Finally, Allspring Global Investments Holdings LLC increased its position in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $20.28 on Friday. The business’s 50-day moving average price is $17.05 and its 200 day moving average price is $18.13. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.64. The company has a market capitalization of $4.79 billion, a PE ratio of 72.43 and a beta of 0.60.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.